Novartis announces encouraging results from Phase III heart failure study Equities.com Nov 12, 2012 (Datamonitor via COMTEX) -- Novartis AG has announced that Phase III RELAX-AHF study has shown that investigational RLX030 improved symptoms and reduced deaths by one-third at the end of six months in patients with acute heart failure, ... |
